-
Je něco špatně v tomto záznamu ?
On the mechanism of miR-29b enhancement of etoposide toxicity in vitro
Z. Dostál, J. Buchtíková, J. Mandrla, M. Modrianský
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
IGA_LF_2022_025
Univerzita Palackého v Olomouci
RVO 61989592
Univerzita Palackého v Olomouci
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- apoptóza účinky léků genetika MeSH
- buňky Hep G2 MeSH
- Caco-2 buňky MeSH
- etoposid * toxicita farmakologie MeSH
- fytogenní protinádorové látky farmakologie toxicita MeSH
- HEK293 buňky MeSH
- HeLa buňky MeSH
- lidé MeSH
- mikro RNA * genetika metabolismus MeSH
- protein MCL-1 * genetika metabolismus MeSH
- protoonkogenní proteiny c-bcl-2 genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
MicroRNA hsa-miR-29 was connected to a number of malignancies. Its target genes are many, among them Mcl-1 that is expressed in three possible isoforms, one of which is anti-apoptotic and another one pro-apoptotic. Ratio of these two isoforms appears to affect cell response to external stimuli. We have demonstrated that miR-29b enhanced etoposide toxicity in HeLa cell line by modulating this ratio of Mcl-1 isoforms. However, it is not known whether the described miR-29 effect is common to various cancer types or even have the opposite effect. This represents a significant problem for possible future applications. In this report, we demonstrate that miR-29b affects toxicity of 60 μM etoposide in cell lines derived from selected malignancies. The mechanism, however, differs among the cell lines tested. Hep G2 cells demonstrated similar effect of miR-29b on etoposide toxicity as was described in HeLa cells, i.e. modulation of Mcl-1 expression. Target protein down-regulated by miR-29b resulting in enhanced etoposide toxicity in Caco-2 cells was, however, Bcl-2 protein. Moreover, H9c2, Hek-293 and ARPE-19 cell lines selected as a representatives of non-malignant cells, showed no effect of miR-29b on etoposide toxicity. Our data suggest that miR-29b could be a common enhancer of etoposide toxicity in malignant cells due to its modulation of Bcl family proteins.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019256
- 003
- CZ-PrNML
- 005
- 20241024111359.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-024-70856-y $2 doi
- 035 __
- $a (PubMed)39191993
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dostál, Zdeněk $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000240028468 $7 xx0267686
- 245 10
- $a On the mechanism of miR-29b enhancement of etoposide toxicity in vitro / $c Z. Dostál, J. Buchtíková, J. Mandrla, M. Modrianský
- 520 9_
- $a MicroRNA hsa-miR-29 was connected to a number of malignancies. Its target genes are many, among them Mcl-1 that is expressed in three possible isoforms, one of which is anti-apoptotic and another one pro-apoptotic. Ratio of these two isoforms appears to affect cell response to external stimuli. We have demonstrated that miR-29b enhanced etoposide toxicity in HeLa cell line by modulating this ratio of Mcl-1 isoforms. However, it is not known whether the described miR-29 effect is common to various cancer types or even have the opposite effect. This represents a significant problem for possible future applications. In this report, we demonstrate that miR-29b affects toxicity of 60 μM etoposide in cell lines derived from selected malignancies. The mechanism, however, differs among the cell lines tested. Hep G2 cells demonstrated similar effect of miR-29b on etoposide toxicity as was described in HeLa cells, i.e. modulation of Mcl-1 expression. Target protein down-regulated by miR-29b resulting in enhanced etoposide toxicity in Caco-2 cells was, however, Bcl-2 protein. Moreover, H9c2, Hek-293 and ARPE-19 cell lines selected as a representatives of non-malignant cells, showed no effect of miR-29b on etoposide toxicity. Our data suggest that miR-29b could be a common enhancer of etoposide toxicity in malignant cells due to its modulation of Bcl family proteins.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a etoposid $x toxicita $x farmakologie $7 D005047
- 650 12
- $a mikro RNA $x genetika $x metabolismus $7 D035683
- 650 12
- $a protein MCL-1 $x genetika $x metabolismus $7 D064549
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a apoptóza $x účinky léků $x genetika $7 D017209
- 650 _2
- $a protoonkogenní proteiny c-bcl-2 $x genetika $x metabolismus $7 D019253
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a fytogenní protinádorové látky $x farmakologie $x toxicita $7 D000972
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a Caco-2 buňky $7 D018938
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Buchtíková, Jana $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Mandrla, Jan $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Modrianský, Martin $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. martin.modriansky@upol.cz $1 https://orcid.org/0000000176920338 $7 xx0042117
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 19880
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39191993 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111353 $b ABA008
- 999 __
- $a ok $b bmc $g 2201853 $s 1231229
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c 1 $d 19880 $e 20240827 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a IGA_LF_2022_025 $p Univerzita Palackého v Olomouci
- GRA __
- $a RVO 61989592 $p Univerzita Palackého v Olomouci
- LZP __
- $a Pubmed-20241015